Arbutus Biopharma (ABUS) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Arbutus Biopharma (ABUS) Misses Q2 EPS by 5c

Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update

August 2, 2018 4:00 PM EDT

- Phase 1a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated

- Phase 1a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half of 2018

- All oral combination Phase 2 study of AB-506 and AB-452 expected to begin by the end of 2019 - Entering second half of year strong financially with $155 million in cash 

Second Quarter Conference Call and Webcast Scheduled Today at 4:30 PM ET

WARMINSTER, Pa., Aug. 02, 2018... More